Chordate Medical Holding AB (publ)
CMH.ST
Stockholm Stock Exchange0.10
SEK
-0.06
- -
Chordate Medical Holding AB (publ)
CMH.ST
(Stockholm Stock Exchange)
Recent
price
0.10
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Chordate Medical Holding AB (publ) is a Swedish medical technology company specializing in the development and commercialization of drug-free neuromodulation treatments for chronic conditions. The company’s core product is Ozilia®, a patented and CE-marked treatment technology based on Kinetic Oscillation Stimulation designed for chronic migraine and chronic rhinitis. Ozilia® offers a neuromodulation solution targeting patients suffering from these chronic diseases by providing an alternative to pharmaceutical medications. Chordate markets Ozilia® primarily through distributors to clinics and hospitals in select European markets, the Middle East, and is expanding presence in Germany and Switzerland. The company was founded in 2005 and is headquartered in Kista, Sweden. Recent major developments include a breakthrough in orders for Ozilia® Migraine in Germany and Saudi Arabia, alongside the initiation of market entry in Switzerland where it signed a distribution agreement with Neurolite AG. The company is actively pursuing an exit strategy, having appointed Partner International Switzerland GmbH as an advisor in late 2024 to seek an international buyer. In 2024, Chordate also ended its joint venture in Shanghai due to unsuccessful product registration in China, while retaining its patent rights. The company continues to implement clinical studies while focusing on scaling sales and increasing installations of its Ozilia® systems in its target markets. Chordate’s business model centers on system sales of the Ozilia® treatment platform and generating recurring revenue through payment per treatment. Its ongoing strategic focus includes expanding regulatory approvals and market penetration in Europe and the Middle East, alongside efforts to secure insurance reimbursement particularly in Germany. The company employs a small team and is publicly traded on the Nasdaq First North Growth Market under the ticker CMH.ST.